Radhika Vattikuti, MD
Endocrinology · Phoenix, AZNPI 1790742682
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.7%), speaking fees and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 40.7% of the total. Reporting peaked in 2020 at $550 and has fallen 65.5% since, to $190 in 2025.
Across 72 payments — averaging $27.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$800
- Abbott$248
- Radius Health, Inc.$189
- Amgen$148
- Sanofi-aventis U.S. LLC$109
- Lifescan, Inc.$74
- plus $398 from 15 others
What the payments were for
- Speaking & faculty fees$80041%
- Food & beverage$1,15459%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 3 | $800 |
| Abbott | 15 | $248 |
| Radius Health, Inc. | 10 | $189 |
| Amgen | 9 | $148 |
| Sanofi-aventis U.S. LLC | 7 | $109 |
| Lifescan, Inc. | 4 | $74 |
| Novo Nordisk | 4 | $68 |
| Lilly USA, LLC | 5 | $65 |
| BD | 2 | $46 |
| AbbVie | 2 | $39 |
| Corcept Therapeutics | 1 | $27 |
| Pfizer | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $14 |
| Medtronic | 1 | $13 |
| Insulet Corporation | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 380 | $483,198 |
| TrulicityDulaglutide | 146 | $256,130 |
| JardianceEmpagliflozin | 74 | $98,575 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $80,793 |
| TymlosAbaloparatide | 21 | $60,994 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $49,143 |
| JanuviaSitagliptin Phosphate | 25 | $32,480 |
| SynthroidLevothyroxine Sodium | 305 | $31,556 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $30,749 |
| Humalog Kwikpen U-100Insulin Lispro | 72 | $25,373 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 150 | $24,631 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $24,470 |
| Novolog FlexpenInsulin Aspart | 58 | $21,283 |
| FarxigaDapagliflozin Propanediol | 18 | $21,029 |
| TresibaInsulin Degludec | 18 | $17,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Tresiba | $68 | $500,965398 claims |
| Lilly USA, LLCTrulicity, Humalog, Insulin Lispro | $65 | $271,652209 claims |
| Radius Health, Inc.Tymlos | $189 | $60,99421 claims |
| AbbVieSynthroid | $39 | $31,556305 claims |
| Sanofi-aventis U.S. LLCLantus | $109 | $8,19342 claims |
| PfizerLevoxyl | $21 | $2,20846 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Phoenix
- Richard DolinarPhoenix$411K
- Chet MonderPhoenix$5K
- Stefan HasinskiPhoenix$1K
- Cristian SciuttoPhoenix$0
- Rohit DwivediSurprise$77K
- Mohamad HoraniChandler$0
- Sapna ShahTucson$0
- Freeman FavorsGlendale$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.